Breaking News

AIkido Pharma Inks Exclusive License for Antiviral Drug Platform

Pan-viral inhibitory compound with efficacy against multiple viral pathogens including Influenza, SARS-COV, MERS-COV, Ebola and Marburg virus

By: Contract Pharma

Contract Pharma Staff

AIkido Pharma Inc. has secured an exclusive world-wide license for a broad spectrum antiviral drug platform. The licensed technology is a broadly acting pan-viral inhibitory compound with efficacy against multiple viral pathogens. The technology works to inhibit replication of multiple viruses including Influenza virus, SARS-COV (coronavirus), MERS-COV, Ebolavirus and Marburg virus.    Anthony Hayes, CEO of AIkido said, “This license is a follow up to our March 6, 2020 press release &#8...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters